Opus Genetics Inc Dossier
Qualitative Analysis
Business overview
Opus Genetics, Inc. (Nasdaq: IRD) is a clinical-stage ophthalmic biopharmaceutical company dedicated to developing first-in-class gene therapies to restore vision and prevent blindness in patients with rare, severe inherited retinal diseases (IRDs). The company was formed following an all-stock merger in October 2024 between Ocuphire Pharma, Inc. and the original private entity, Opus Genetics (which was launched in 2021 by the Foundation Fighting Blindness's venture arm, the RD Fund). Opus Genetics utilizes adeno-associated virus (AAV)-based vectors to deliver functional genes directly to affected retinal cells. Its pipeline features seven AAV-based programs, led by OPGx-LCA5 for LCA5-associated Leber congenital amaurosis and OPGx-BEST1 for BEST1-related retinal degeneration. Additionally, the company maintains a small-molecule portfolio addressing broader retinal and refractive disorders, including Phentolamine Ophthalmic Solution 0.75% and APX3330.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Secured a strategic financing agreement with Oberland Capital Management providing up to $155 million in flexible funding, including an initial $35 million upfront tranche and a $5 million equity investment.
Expected impact: Provides the capital needed to complete pivotal studies for lead programs OPGx-LCA5 and OPGx-BEST1, and to advance three earlier-stage programs into clinical testing.
Advancing three earlier-stage gene therapy programs (OPGx-RDH12, OPGx-MERTK, and OPGx-RHO) into clinical testing over the next 12 to 18 months.
Expected impact: Broadens the clinical-stage portfolio and positions the company to capture multiple Priority Review Voucher opportunities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
All-stock merger to create a leading clinical-stage gene therapy franchise focused on rare inherited retinal diseases, combining Ocuphire's late-stage ophthalmic development experience with Opus's gene therapy pipeline.
Financial impact: Expanded the pipeline to seven AAV-based gene therapy assets and extended the combined company's cash runway.
Strategic Partnerships
Accelerates the development of OPGx-RDH12, a gene therapy program targeting RDH12-associated Leber congenital amaurosis.
Terms: The Alliance will contribute up to $1.6 million towards the development of the program under a risk-sharing structure with performance-based milestones.
Supports the clinical initiation of the OPGx-MERTK program, targeting retinitis pigmentosa, with clinical testing to be conducted at Cleveland Clinic Abu Dhabi.
Terms: Funding is supported by a consortium led by Abu Dhabi's Healthcare Research and Innovation Fund.
Provides process and analytical development, quality control testing, and GMP manufacturing services for Opus's AAV vector-based gene therapies.
Terms: Not explicitly disclosed.